Three-month ad interim analysis of total anti-SARS-CoV-2 antibodies in healthy recipient of a single BNT162b2 vaccine booster
| Errataetall: |
CommentOn: Clin Chem Lab Med. 2022 Apr 27;60(7):1110-1115. - PMID 35473824 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:60 |
|---|---|
| Enthalten in: |
Clinical chemistry and laboratory medicine - 60(2022), 8 vom: 26. Juli, Seite e181-e183 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Salvagno, Gian Luca [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies |
|---|
| Anmerkungen: |
Date Completed 21.06.2022 Date Revised 04.08.2022 published: Electronic-Print CommentOn: Clin Chem Lab Med. 2022 Apr 27;60(7):1110-1115. - PMID 35473824 Citation Status MEDLINE |
|---|
| doi: |
10.1515/cclm-2022-0385 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340850604 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340850604 | ||
| 003 | DE-627 | ||
| 005 | 20231226010419.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1515/cclm-2022-0385 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1136.xml |
| 035 | |a (DE-627)NLM340850604 | ||
| 035 | |a (NLM)35562102 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Salvagno, Gian Luca |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Three-month ad interim analysis of total anti-SARS-CoV-2 antibodies in healthy recipient of a single BNT162b2 vaccine booster |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.06.2022 | ||
| 500 | |a Date Revised 04.08.2022 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a CommentOn: Clin Chem Lab Med. 2022 Apr 27;60(7):1110-1115. - PMID 35473824 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antibodies | |
| 650 | 4 | |a immune response | |
| 650 | 4 | |a vaccination | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a N38TVC63NU |2 NLM | |
| 700 | 1 | |a Henry, Brandon M |e verfasserin |4 aut | |
| 700 | 1 | |a Pighi, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a De Nitto, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Gianfilippi, Gianluca |e verfasserin |4 aut | |
| 700 | 1 | |a Lippi, Giuseppe |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical chemistry and laboratory medicine |d 1998 |g 60(2022), 8 vom: 26. Juli, Seite e181-e183 |w (DE-627)NLM095304118 |x 1437-4331 |7 nnns |
| 773 | 1 | 8 | |g volume:60 |g year:2022 |g number:8 |g day:26 |g month:07 |g pages:e181-e183 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1515/cclm-2022-0385 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 60 |j 2022 |e 8 |b 26 |c 07 |h e181-e183 | ||